Some GLP-1 injections recalled due to 'lack of assurance of sterility'

This is read by an automated voice.Please report any issues or inconsistencies here.

See more from the L.A.Times in Google Search.

Set us as preferred Dozens of vials of compounded GLP-1 injections have been recalled due to a lack of assurance that the products are sterile, according to the U.S.Food and Drug Administration.

The compounding pharmacy that issued the recall was previously reprimanded by the FDA for “serious deficiencies” in their practices.Here’s what you need to know.

Science & Medicine Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S.saying they currently take the medications.Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of Tirzepatide injections last month due to a “lack of assurance of sterility,” according to the official announcement.

The recall classification was updated this month to Class ll — meaning exposure to the product may cause temporary or medically reversible adverse health consequences.However, the probability of serious adverse health effects is still considered low.

The FDA previously sent Apothecary Pharma a warning letter in December stating that the company failed to properly label the drug at its outsourcing facility in North Carolina.Some of the labels did not include: Over the course of several inspections in September 2024, and three visits in January and May 2025, “investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk,” according to the FDA’s December letter.

Specific code information on the recalled products can be found here.Science & Medicine U.S.

inspectors found egregious conditions at two Chinese factories making key components for compounded GLP-1 drugs popular in America, including black mold and “gross contamination” at one plant.A compounded GLP-1 is made when a pharmacy formulates a cu...